Aldoxorubicin in soft tissue sarcomas

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Cancer Research UK . Soft tissue sarcoma incidence statistics (2010). www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/soft-tissue-sarcoma/incidence#heading-Zero.
  Google Scholar
• 2 American Cancer Society . Key statistics for soft tissue sarcomas (2019). www.cancer.org/cancer/soft-tissue-sarcoma/about/key-statistics.html
  Google Scholar
• 3 Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. Clin. Sarcoma Res. 6, 20 (2016).
  MedlineGoogle Scholar
• 4 Van Der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled Phase III trial. Lancet 379(9829), 1879–1886 (2012).
  MedlineGoogle Scholar
• 5 Demetri GD, Von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347(7), 472–480 (2002).
  Medline CASGoogle Scholar
• 6 Demetri GD, Van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet 368(9544), 1329–1338 (2006).
  Medline CASGoogle Scholar
• 7 Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, Phase III trial. Lancet 381(9863), 295–302 (2013).
  Medline CASGoogle Scholar
• 8 Noujaim J, Thway K, Sheri A, Keller C, Jones RL. Histology-driven therapy: the importance of diagnostic accuracy in guiding systemic therapy of soft tissue tumors. Int. J. Surg. Pathol. 24(1), 5–15 (2016).
  Medline CASGoogle Scholar
• 9 In GK, Hu JS, Tseng WW. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther. Adv. Med. Oncol. 9(8), 533–550 (2017).
  Medline CASGoogle Scholar
• 10 Bui-Nguyen B, Butrynski JE, Penel N et al. A Phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Eur. J. Cancer 51(10), 1312–1320 (2015).
  Medline CASGoogle Scholar
• 11 Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J. Pharm. Pharmacol. 65(2), 157–170 (2013).
  Medline CASGoogle Scholar
• 12 Antman K, Crowley J, Balcerzak SP et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 11(7), 1276–1285 (1993).
  Medline CASGoogle Scholar
• 13 Judson I, Verweij J, Gelderblom H et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled Phase III trial. Lancet Oncol. 15(4), 415–423 (2014). • Results of the EORTC 62012 trial which did not demonstrate superiority of combination doxorubicin with ifosfamide for improving overall survival (OS) in metastatic or locally advanced soft tissue sarcomas. However, there was an improvement in odds ratio with combination therapy but with an increase in grade 3–4 toxicity.
  Medline CASGoogle Scholar
• 14 Lorigan P, Verweij J, Papai Z et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J. Clin. Oncol. 25(21), 3144–3150 (2007).
  Medline CASGoogle Scholar
• 15 Ryan CW, Merimsky O, Agulnik M et al. PICASSO III: a Phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J. Clin. Oncol. 34(32), 3898–3905 (2016).
  Medline CASGoogle Scholar
• 16 Tap WD, Papai Z, Van Tine BA et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised Phase III trial. Lancet Oncol. 18(8), 1089–1103 (2017).
  Medline CASGoogle Scholar
• 17 Seddon B, Strauss SJ, Whelan J et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled Phase III trial. Lancet Oncol. 18(10), 1397–1410 (2017).
  Medline CASGoogle Scholar
• 18 Tap WD, Jones RL, Van Tine BA et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label Phase Ib and randomised Phase II trial. Lancet 388(10043), 488–497 (2016). • Results of the Phase II trial comparing doxorubicin monotherapy with combination olaratumab and doxorubicin confirmed superiority of combination therapy in improving progression-free survival and odds ratio in locally advanced and metastatic soft tissue sarcomas.
  Medline CASGoogle Scholar
• 19 Source: Lilly. Lilly reports results of Phase 3 soft tissue sarcoma study of LARTRUVO^® (2019). Press release: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-results-phase-3-soft-tissue-sarcoma-study.
  Google Scholar
• 20 Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J. Clin. Oncol. 26(32), 5269–5274 (2008).
  Medline CASGoogle Scholar
• 21 Demetri GD, Von Mehren M, Jones RL et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a Phase III randomized multicenter clinical trial. J. Clin. Oncol. 34(8), 786–793 (2016).
  Medline CASGoogle Scholar
• 22 Schoffski P, Chawla S, Maki RG et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, Phase III trial. Lancet 387(10028), 1629–1637 (2016).
  Medline CASGoogle Scholar
• 23 García-Del-Muro X, López-Pousa A, Maurel J et al. Randomized Phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas Study. J. Clin. Oncol. 29(18), 2528–2533 (2011).
  Medline CASGoogle Scholar
• 24 Mita MM, Natale RB, Wolin EM et al. Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Invest. New Drugs 33(2), 341–348 (2015). •• Pharmacokinetic study in patients with solid tissue tumors to establish toxicity profile and recommended dosing schedule.
  Medline CASGoogle Scholar
• 25 Speth PA, Van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin. Pharma. 15(1), 15–31 (1988).
  CASGoogle Scholar
• 26 Unger C, Haring B, Medinger M et al. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin. Cancer Res. 13(16), 4858–4866 (2007). •• First pharmacokinetic study that confirmed acceptable safety and maximum tolerated dose for further Phase II studies in patients with solid tissue tumors.
  Medline CASGoogle Scholar
• 27 Kratz F, Ehling G, Kauffmann HM, Unger C. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Hum. Exp. Toxicol. 26(1), 19–35 (2007).
  Medline CASGoogle Scholar
• 28 Chawla SP, Chua VS, Hendifar AF et al. A Phase IB/II study of aldoxorubicin in patients with soft tissue sarcoma. Cancer 121(4), 570–579 (2015). •• First Phase Ib/II study of aldoxorubicin use in patients with locally advanced or metastatic soft tissue sarcomas. Demonstrated acceptable safety and preliminary efficacy.
  Medline CASGoogle Scholar
• 29 Chawla SP, Sankhala KK, Chawla S et al. A Phase I/II study of continuous infusion ifosfamide/mesna+aldoxorubicin in sarcoma patients. J. Clin. Oncol. 34(15 Suppl.), e22547–e22547 (2016).
  Google Scholar
• 30 Chawla SP, Papai Z, Mukhametshina G et al. First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a Phase IIb randomized clinical trial. JAMA Oncol. 1(9), 1272–1280 (2015). • First Phase II trial that showed superiority of aldoxorubicin over doxorubicin in progression-free survival and odds ratio and manageable toxicity profile.
  MedlineGoogle Scholar
• 31 Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Rel. 132(3), 171–183 (2008).
  Medline CASGoogle Scholar
• 32 Lebrecht D, Geist A, Ketelsen UP et al. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int. J. Cancer 120(4), 927–934 (2007).
  Medline CASGoogle Scholar
• 33 Chawla SP, Ganjoo KN, Schuetze S et al. Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas. J. Clin. Oncol. 35(15 Suppl.), 11000–11000 (2017).
  Google Scholar
• 34 Chawla SP, Papai Z, Sankhala K et al. Randomized Phase IIb trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas. 32(15 Suppl.), 10502–10502 (2014).
  Google Scholar
• 35 Eilber FC, Sankhala KK, Chawla SP et al. Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas. 35(15 Suppl.), 11051–11051 (2017).
  Google Scholar